http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0699194-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2b9dc89cc4ba060cc73bbf0c90bbb78 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 |
| filingDate | 1994-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cf65da26404caedcb7e190baac1bbfb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_123b8ffcaf5460cda2002f105db51a95 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58f85c92ab988607a725d952374690a2 |
| publicationDate | 1996-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0699194-A1 |
| titleOfInvention | 5-ht4 receptor antagonists |
| abstract | Compounds of formula (I) and pharmaceutically acceptable salts thereof, and the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof: <?in-line-formulae description="In-line Formulae" end="lead"?>X-CO-CH<SUB>2</SUB>-Z <?in-line-formulae description="In-line Formulae" end="tail"?> wherein X is a monocyclic or polycyclic aromatic group, Z is of sub-formula (h), (j) or (k): wherein n<SUP>1 </SUP>is 1, 2, 3 or 4; n<SUP>2 </SUP>is 0, 1, 2, 3 or 4; n<SUP>3</SUP>is 2, 3, 4 or 5; q is 0, 1, 2 or 3; p is 0, 1 or 2; m is 0, 1 or 2; R<SUB>5 </SUB>is hydrogen, C<SUB>1-2 </SUB>alkyl, aralkyl or R<SUB>5 </SUB>is (CH<SUB>2</SUB>)<SUB>z</SUB>-R<SUB>10 </SUB>wherein z is 2 or 3 and R<SUB>10 </SUB>is selected from cyano, hydroxyl, C<SUB>1-6 </SUB>alkoxy, phenoxy, C(O)C<SUB>1-6 </SUB>alkyl, COC<SUB>6</SUB>H<SUB>5</SUB>, -CONR<SUB>11</SUB>R<SUB>12</SUB>, NR<SUB>11</SUB>COR<SUB>12</SUB>, SO<SUB>2</SUB>NR<SUB>11</SUB>R<SUB>12 </SUB>or NR<SUB>11</SUB>SO<SUB>2</SUB>R<SUB>12 </SUB>wherein R<SUB>11 </SUB>and R<SUB>12 </SUB>are hydrogen or C<SUB>1-6 </SUB>alkyl; or R<SUB>5 </SUB>is straight or branched chain alkylene of chain length 1-6 carbon atoms terminally substituted by aryl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 5 or 6 membered monocyclic heteroaryl or 9 or 10 membered fused bicyclic heteroaryl linked through carbon, C<SUB>2-7 </SUB>alkoxycarbonyl, or secondary or tertiary hydroxy substituted C<SUB>1-6 </SUB>alkyl; ; and R<SUB>6</SUB>, R<SUB>7 </SUB>and R<SUB>8 </SUB>are independently hydrogen or C<SUB>1-6 </SUB>alkyl; and R<SUB>9 </SUB>is hydrogen or C<SUB>1-10</SUB>alkyl; and their use as pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and CNS disorders. |
| priorityDate | 1993-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 133.